<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Biopharma Credit Plc — News on 6ix</title>
<link>https://6ix.com/company/biopharma-credit-plc</link>
<description>Latest news and press releases for Biopharma Credit Plc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 10 Apr 2026 06:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/biopharma-credit-plc" rel="self" type="application/rss+xml" />
<item>
<title>Investor Presentation via Investor Meet Company</title>
<link>https://6ix.com/company/biopharma-credit-plc/news/investor-presentation-via-investor-meet-company-128</link>
<guid isPermaLink="true">https://6ix.com/company/biopharma-credit-plc/news/investor-presentation-via-investor-meet-company-128</guid>
<pubDate>Fri, 10 Apr 2026 06:00:00 GMT</pubDate>
<description>BioPharma Credit PLC has announced that its Investment Adviser, Pharmakon Advisors, LP, will host a live investor presentation on April 21, 2026, at 15:00 BST via Investor Meet Company. This session is open to both existing and potential shareholders and will focus on the company's investment strategy and portfolio. Questions can be submitted in advance by April 20, 2026, at 09:00 BST, or during the presentation itself.
Disclaimer*</description>
</item>
<item>
<title>NEW INVESTMENT OF US$125 MILLION</title>
<link>https://6ix.com/company/biopharma-credit-plc/news/new-investment-of-usdollar125-million</link>
<guid isPermaLink="true">https://6ix.com/company/biopharma-credit-plc/news/new-investment-of-usdollar125-million</guid>
<pubDate>Tue, 17 Mar 2026 07:00:00 GMT</pubDate>
<description>BioPharma Credit PLC has announced a new senior secured loan agreement with Zenas BioPharma, Inc., committing up to US$125 million through its subsidiary and an additional US$125 million from BioPharma Credit Investments V (Master) LP. The investment will be disbursed across five tranches, with the first US$37.5 million funded shortly after execution, and subsequent tranches available through April 2029, contingent on regulatory approvals and sales milestones. The loan matures in March 2031, bea</description>
</item>
<item>
<title>Net Asset Value(s) and Monthly Factsheet</title>
<link>https://6ix.com/company/biopharma-credit-plc/news/net-asset-values-and-monthly-factsheet</link>
<guid isPermaLink="true">https://6ix.com/company/biopharma-credit-plc/news/net-asset-values-and-monthly-factsheet</guid>
<pubDate>Fri, 20 Feb 2026 16:00:00 GMT</pubDate>
<description>Net Asset Value(s) and Monthly Factsheet.</description>
</item>
<item>
<title>Dividend Declaration</title>
<link>https://6ix.com/company/biopharma-credit-plc/news/dividend-declaration-66</link>
<guid isPermaLink="true">https://6ix.com/company/biopharma-credit-plc/news/dividend-declaration-66</guid>
<pubDate>Tue, 10 Feb 2026 17:20:00 GMT</pubDate>
<description>BioPharma Credit PLC has declared an interim dividend of 3.196044 cents per share, comprising a 1.75 cent ordinary dividend and a 1.446044 cent special dividend, payable on March 20, 2026. This brings the total dividends declared for the 2025 calendar year to 9.95 cents per share, with total dividends paid since IPO reaching 76.88 cents. The company aims for a 7-cent base annual dividend, supplemented by special distributions from excess income. The ex-dividend date is February 19, 2026, and the</description>
</item>
<item>
<title>Notice of Full Year Results</title>
<link>https://6ix.com/company/biopharma-credit-plc/news/notice-of-full-year-results-9</link>
<guid isPermaLink="true">https://6ix.com/company/biopharma-credit-plc/news/notice-of-full-year-results-9</guid>
<pubDate>Tue, 03 Feb 2026 07:00:00 GMT</pubDate>
<description>BioPharma Credit PLC will announce its audited full-year results for the period ending December 31, 2025, on March 24, 2026. A management presentation will be held via webcast at 14:00 GMT.
Disclaimer*</description>
</item>
<item>
<title>STATEMENT RE COLLEGIUM PREPAYMENT</title>
<link>https://6ix.com/company/biopharma-credit-plc/news/statement-re-collegium-prepayment</link>
<guid isPermaLink="true">https://6ix.com/company/biopharma-credit-plc/news/statement-re-collegium-prepayment</guid>
<pubDate>Tue, 30 Dec 2025 13:32:00 GMT</pubDate>
<description>BioPharma Credit PLC has received a prepayment of US$261.4 million in principal, US$2.6 million in fees, and US$5.3 million in accrued interest from Collegium Pharmaceutical, Inc. for the senior secured term loan initially valued at US$645.8 million, of which BioPharma Credit had a US$290.4 million investment. This prepayment brings BioPharma Credit's cash balance to approximately US$405 million, and the company anticipates diversifying its portfolio with this increased liquidity.
</description>
</item>
<item>
<title>Director/PDMR Shareholding</title>
<link>https://6ix.com/company/biopharma-credit-plc/news/directorpdmr-shareholding-305</link>
<guid isPermaLink="true">https://6ix.com/company/biopharma-credit-plc/news/directorpdmr-shareholding-305</guid>
<pubDate>Tue, 04 Nov 2025 15:29:00 GMT</pubDate>
<description>BioPharma Credit PLC announced on November 4, 2025, that Anita Hyman, a person closely associated with Director Harry Hyman, acquired 62 ordinary shares of $0.01 each. This transaction, which took place on November 3, 2025, on the London Stock Exchange, was a purchase resulting from dividend reinvestment. Each share was acquired at a price of £0.693518. This increase in a director-linked holding could be perceived as a minor positive indicator for the company's stock.
Disclaimer*</description>
</item>
<item>
<title>UPDATES ON INVESTMENT PORTFOLIO</title>
<link>https://6ix.com/company/biopharma-credit-plc/news/updates-on-investment-portfolio</link>
<guid isPermaLink="true">https://6ix.com/company/biopharma-credit-plc/news/updates-on-investment-portfolio</guid>
<pubDate>Tue, 21 Oct 2025 06:00:00 GMT</pubDate>
<description>BioPharma Credit PLC announced updates to its investment portfolio, including the completion of BioCryst Pharmaceuticals' European ORLADEYO® sale and final loan repayment. The company received US$2.6 million in accrued interest and prepayment fees related to the repayment of US$79.5 million, which was part of an original US$120 million investment in a senior secured loan to BioCryst. Additionally, BioPharma Credit PLC funded US$30 million to Valneva Austria GmbH, alongside BioPharma Credit Inves</description>
</item>
<item>
<title>NEW INVESTMENT OF US$30 MILLION</title>
<link>https://6ix.com/company/biopharma-credit-plc/news/new-investment-of-usdollar30-million</link>
<guid isPermaLink="true">https://6ix.com/company/biopharma-credit-plc/news/new-investment-of-usdollar30-million</guid>
<pubDate>Tue, 07 Oct 2025 06:00:00 GMT</pubDate>
<description>BioPharma Credit PLC announced a new US$30 million investment in Valneva Austria GmbH, a subsidiary of Valneva SE, through a senior secured loan agreement. BioPharma Credit Investments V (Master) LP will invest an additional US$185 million in parallel. Further tranches of up to US$285 million are possible for business development, subject to mutual agreement. The loan, maturing in October 2030, will bear interest at 9.00 per cent per annum. This marks the third investment in Valneva by entities </description>
</item>
<item>
<title>Half-year Report</title>
<link>https://6ix.com/company/biopharma-credit-plc/news/half-year-report-153</link>
<guid isPermaLink="true">https://6ix.com/company/biopharma-credit-plc/news/half-year-report-153</guid>
<pubDate>Mon, 22 Sep 2025 06:00:00 GMT</pubDate>
<description>BioPharma Credit PLC reported a net income per share of 6.33 cents for the half year ended June 30, 2025, which substantially covers the annual dividend target of 7 cents. The company continued its share buybacks, purchasing $50 million worth of shares during the period. A special dividend of 1.5 cents was declared post period-end, bringing total dividends for the calendar year to date to 6.75 cents per share. New investment commitments totaled $144.2 million, including a $104.2 million refinanc</description>
</item>
<item>
<title>NEW INVESTMENT OF UP TO US$62.5 MILLION</title>
<link>https://6ix.com/company/biopharma-credit-plc/news/new-investment-of-up-to-usdollar625-million</link>
<guid isPermaLink="true">https://6ix.com/company/biopharma-credit-plc/news/new-investment-of-up-to-usdollar625-million</guid>
<pubDate>Wed, 03 Sep 2025 11:21:00 GMT</pubDate>
<description>BioPharma Credit PLC announced a new investment of up to US$62.5 million in Precigen, Inc. through a senior secured loan agreement. A parallel investment of up to an additional US$62.5 million will be made by BioPharma Credit Investments V (Master) LP, with BioPharma Credit PLC acting as collateral agent. The initial US$50 million Tranche A was drawn on September 3, 2025. A second tranche of US$12.5 million is available until June 29, 2027, subject to conditions. The loan matures in September 20</description>
</item>
<item>
<title>Total Voting Rights</title>
<link>https://6ix.com/company/biopharma-credit-plc/news/total-voting-rights-539</link>
<guid isPermaLink="true">https://6ix.com/company/biopharma-credit-plc/news/total-voting-rights-539</guid>
<pubDate>Mon, 01 Sep 2025 13:26:00 GMT</pubDate>
<description>BioPharma Credit PLC announced that as of August 31, 2025, the company's issued share capital consists of 1,373,932,067 ordinary shares with a nominal value of $0.01 each. The total number of shares in circulation is 1,129,227,778, each carrying one voting right, resulting in a total of 1,129,227,778 voting rights. The company holds 244,704,289 shares in treasury. This total voting rights figure can be used by shareholders to determine if they need to notify their interest in BioPharma Credit PL</description>
</item>
<item>
<title>Notice of Half Year Results</title>
<link>https://6ix.com/company/biopharma-credit-plc/news/notice-of-half-year-results-13</link>
<guid isPermaLink="true">https://6ix.com/company/biopharma-credit-plc/news/notice-of-half-year-results-13</guid>
<pubDate>Tue, 26 Aug 2025 06:00:00 GMT</pubDate>
<description>BioPharma Credit PLC will announce its Half Year Results for the period ending June 30, 2025, on Monday, September 22, 2025. A management presentation regarding these results will be delivered via webcast at 14:00 BST.
Disclaimer*</description>
</item>
<item>
<title>Transaction in Own Shares - Correction</title>
<link>https://6ix.com/company/biopharma-credit-plc/news/transaction-in-own-shares-correction-5</link>
<guid isPermaLink="true">https://6ix.com/company/biopharma-credit-plc/news/transaction-in-own-shares-correction-5</guid>
<pubDate>Thu, 21 Aug 2025 11:07:00 GMT</pubDate>
<description>BioPharma Credit PLC issued a correction to its August 20, 2025, announcement regarding its own share purchase. The correction adjusts the highest and lowest price per share from $0.8900 to $0.8860. On August 20, 2025, the company purchased 100,000 ordinary shares at a weighted average price of $0.8860 per share on the London Stock Exchange (LSE). Following this transaction, the company holds 244,704,289 treasury shares and has 1,129,227,778 ordinary shares in issue (excluding treasury shares)</description>
</item>
<item>
<title>Transaction in Own Shares</title>
<link>https://6ix.com/company/biopharma-credit-plc/news/transaction-in-own-shares-156</link>
<guid isPermaLink="true">https://6ix.com/company/biopharma-credit-plc/news/transaction-in-own-shares-156</guid>
<pubDate>Wed, 20 Aug 2025 17:16:00 GMT</pubDate>
<description>BioPharma Credit plc announced the purchase of 100,000 of its ordinary shares on August 20, 2025, at a price range of $0.8900 to $0.8900 per share, through J.P. Morgan Securities plc on the LSE. The weighted average price was $0.8860 per share. Following this transaction, the company holds 244,704,289 treasury shares and has 1,129,227,778 ordinary shares in issue (excluding treasury shares), resulting in a total of 1,129,227,778 voting rights.
Disclaimer*</description>
</item>
<item>
<title>Appointment of New Director</title>
<link>https://6ix.com/company/biopharma-credit-plc/news/appointment-of-new-director-4</link>
<guid isPermaLink="true">https://6ix.com/company/biopharma-credit-plc/news/appointment-of-new-director-4</guid>
<pubDate>Thu, 31 Jul 2025 06:00:00 GMT</pubDate>
<description>Appointment of New Director.</description>
</item>
<item>
<title>Holding(s) in Company</title>
<link>https://6ix.com/company/biopharma-credit-plc/news/holdings-in-company-320</link>
<guid isPermaLink="true">https://6ix.com/company/biopharma-credit-plc/news/holdings-in-company-320</guid>
<pubDate>Fri, 18 Jul 2025 15:23:00 GMT</pubDate>
<description>Holding(s) in Company.</description>
</item>
<item>
<title>STATEMENT RE BIOCRYST</title>
<link>https://6ix.com/company/biopharma-credit-plc/news/statement-re-biocryst</link>
<guid isPermaLink="true">https://6ix.com/company/biopharma-credit-plc/news/statement-re-biocryst</guid>
<pubDate>Tue, 01 Jul 2025 11:02:00 GMT</pubDate>
<description>STATEMENT RE BIOCRYST.</description>
</item>
<item>
<title>Director Declaration</title>
<link>https://6ix.com/company/biopharma-credit-plc/news/director-declaration-133</link>
<guid isPermaLink="true">https://6ix.com/company/biopharma-credit-plc/news/director-declaration-133</guid>
<pubDate>Tue, 10 Jun 2025 09:56:00 GMT</pubDate>
<description>Director Declaration.</description>
</item>
<item>
<title>Result of AGM</title>
<link>https://6ix.com/company/biopharma-credit-plc/news/result-of-agm-276</link>
<guid isPermaLink="true">https://6ix.com/company/biopharma-credit-plc/news/result-of-agm-276</guid>
<pubDate>Mon, 09 Jun 2025 15:37:00 GMT</pubDate>
<description>Result of AGM.</description>
</item>
</channel>
</rss>